Hyundai Bio Science, led by CEO Sang-ki Oh, announced on March 12th its acquisition of a 23% stake and management rights in ADM Korea, a clinical trial outsourcing agency listed on KOSDAQ, for $15.4 million. AIDM Korea, boasting around 180 clinical experts and extensive expertise, is poised to generate significant synergy effects in advancing the commercialization of Hyundai Bio's 'Xafty'.

Xafty, hailed by Hyundai Bio as a prime contender for a universal antiviral drug, holds the potential to combat over 220 strains of viral diseases across 16 categories. This efficacy stems from its autophagic mechanism, which indiscriminately eliminates viruses regardless of type or mutation. Its key component, 'Niclosamide,' has exhibited antiviral effectiveness against 33 representative viral diseases spanning 16 categories, including COVID-19, MERS, AIDS, and Ebola, as documented in prestigious scientific publications worldwide.

CEO Oh of Hyundai Bio expressed, "The acquisition of the CRO is part of our strategy to lead the global universal antiviral drug market."